Advertisement
Abstract| Volume 92, SUPPLEMENT 1, S7, March 2018

Altered type III collagen turnover measured in pre-treatment serum predicts outcome in metastatic melanoma patients treated with Ipilimumab

DOI:https://doi.org/10.1016/j.ejca.2018.01.019
Altered type III collagen turnover measured in pre-treatment serum predicts outcome in metastatic melanoma patients treated with Ipilimumab
Previous ArticleA new combination immunotherapy approach with anti-PD-L1 and HER2/neu loaded dendritic cell vaccine along with saponin adjuvant
Next ArticleHumanized mouse models of triple-negative and triple-positive breast cancer for preclinical validation of novel immuno-oncology therapies
      Background: Altered tissue remodeling and collagen turnover in the tumor microenvironment can affect drug delivery as well as T-cell infiltration and activity and hereby affect response to immune checkpoint inhibitors. The aim of this study was to evaluate the association between serum biomarkers of type III collagen formation and degradation and outcome in metastatic melanoma patients treated with Ipilimumab (Ipi).
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      Article info

      Publication history

      P02. Tumor immunity and microenvironment P02.01

      Identification

      DOI: https://doi.org/10.1016/j.ejca.2018.01.019

      Copyright

      © 2018 Published by Elsevier Inc.

      ScienceDirect

      Access this article on ScienceDirect
      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.


      RELX